Using contrast-enhanced ultrasound to check Y-90 radioembolization response in liver cancer
Official title: Contrast-Enhanced Ultrasound Evaluation of Radioembolization Treatment Response
Run by Thomas Jefferson University · NCT07145801 · Data updated 2026-11-12
This will test whether contrast-enhanced ultrasound (CEUS) can show treatment response to Y‑90 radioembolization in people with newly diagnosed hepatocellular carcinoma who are scheduled for TARE.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Thomas Jefferson University Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | September 11, 2025 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | June 10, 2026 |
| Trial ID | NCT07145801 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with treatment‑naïve HCC visible on ultrasound who are medically stable, scheduled for TARE, and able to consent (with a negative pregnancy test if applicable).
✕Probably not a fit
Patients who are medically unstable, seriously or terminally ill, have tumors not visible on ultrasound, or have known sensitivities to Lumason or Sonazoid are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective Phase 2 study enrolls 30 patients with treatment‑naïve hepatocellular carcinoma visible on ultrasound who are scheduled to receive Y‑90 transarterial radioembolization (TARE). Baseline ultrasound and dual CEUS exams will be performed using Lumason followed by Sonazoid with timed imaging of arterial, late vascular, and Kupffer phases, and data exported for offline analysis. Imaging findings will be compared to the clinical course and routine post‑TARE imaging follow‑up to determine whether CEUS detects viable tumor earlier than standard CT/MRI criteria. Participants will be followed for at least six months after TARE to capture treatment response and any need for retreatment or transplant listing.
Why it matters
Potential benefit: If successful, CEUS could detect viable tumor earlier after TARE, enabling faster retreatment decisions and earlier transplant consideration.
How similar studies have gone: Prior CEUS work in HCC has shown promise for characterizing tumor vascularity and response, but using dual‑contrast CEUS specifically for early post‑TARE response is relatively novel and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Scheduled for TARE therapy of a treatment naïve HCC visible on ultrasound. * Be at least 18 years of age. * Be medically stable. * If a female of child-bearing age, must have a negative pregnancy test. * Have signed Informed Consent to participate in the study. Exclusion Criteria: * Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. * Patients with known sensitivities to the components of Lumason. * Patients with known sensitivities to the components of Sonazoid.
Where it's running
-
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: John Eisenbrey, PhD — Thomas Jefferson University
- Study coordinator: Site Public Contact
- Email: ONCTrialNow@jefferson.edu
- Phone: 215-600-9151
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood test for detecting liver cancer and cirrhosis
This study is testing a new blood test to see if it can help detect liver cancer and cirrhosis in people who have or are being checked for liver issues.
-
BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer
This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.
-
MRI-guided adaptive single-session radiation for liver tumors (SABR)
This trial will test a single-session, MRI-guided adaptive high-dose radiation (SABR) for adults with primary or metastatic liver tumors to see if on-table MRI planning and replanning can treat tumors without a separate simulation visit.
-
Tracking immune and genomic changes in liver cancer during immunotherapy
This study will test whether blood and tumor biomarkers can predict how people with advanced hepatocellular carcinoma respond to immunotherapy.
-
Assessing blood biomarkers and MRI for liver cancer patients undergoing radiation therapy
This study is testing if using special MRI scans and blood tests can help doctors keep track of liver health in patients with liver cancer who are getting radiation therapy.
-
Combining TACE and surgery for large liver tumors
This study is testing if a treatment called TACE before surgery can help people with large liver tumors do better after surgery and have fewer chances of the cancer coming back.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.